

Emergent BioSolutions to Present at Morgan Keegan Homeland Security Technology Conference 2007

May 18, 2007

ROCKVILLE, Md.--(BUSINESS WIRE)--May 18, 2007--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will present at the Morgan Keegan Homeland Security Technology 2007 Conference on May 22, 2007 at 2:10 pm Eastern Time at The New York Palace Hotel, New York City. Company management will participate in a panel discussion focused on issues related to biological protection and will also provide a corporate overview including an update of the company's product development programs and recent corporate activities.

A webcast of the presentation will be available both live and by replay. To access both the live and archived webcast, please go to www.emergentbiosolutions.com, click on the "Investors" link and proceed to the "Webcasts & Presentations" section. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

CONTACT: Emergent BioSolutions Inc. Investors or Media: Robert G. Burrows, Vice President, Corporate Communications 301-795-1877 burrowsr@ebsi.com

SOURCE: Emergent BioSolutions Inc.